Correction: McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685
1
Department of Microbiology and Immunology, University of Otago, Dunedin 9016, New Zealand
2
Otago Micro and Nano Imaging, University of Otago, Dunedin 9016, New Zealand
*
Authors to whom correspondence should be addressed.
Cancers 2020, 12(3), 553; https://doi.org/10.3390/cancers12030553
Submission received: 20 January 2020
/
Accepted: 21 February 2020
/
Published: 28 February 2020
The authors wish to make the following corrections to this paper [1]:
On page 14, in paragraph two of Chapter 4, Echoviruses, the sentence: “The United States, much of the European Union and Japan found a lack of experimental evidence to approve Rigvir in cancer treatment [99]” should be deleted.
On page 15, line one, the sentence: “One such retrospective study showed a statistically significant increase in 3-year survival of melanoma patients when treated with Rigvir post-surgery than surgery alone or with other immunomodulators [97]”, should be changed to: “One such retrospective study showed a statistically significant 4.39–6.57-fold decrease in mortality of melanoma patients when treated with Rigvir post-surgery than surgery alone [97]”.
On page 15, line three, the sentence: “For best efficacy, Rigvir is injected intratumourally rather than intramuscularly, increasing 5-year survival between 29.9% and 19.5% [97]” should be deleted.
On page 15, paragraph two, line seven, the sentence “In the case of the stage IV histiocytic sarcoma patient, Rigvir was administered as part of a therapeutic cocktail including multisite radiation therapy, doxorubicin, cyclophosphamide and helixor P” should read: “In the case of the stage IV histiocytic sarcoma patient, Rigvir was administered for about 2 years followed by multisite radiation therapy, doxorubicin, cyclophosphamide and helixor P.”
On page 15, paragraph three, line two, the sentence “One patient with a basal cell carcinoma, a diagnosis with a median expected survival of five months, was treated with Rigvir post-surgery [101]” should read: “One patient with melanoma unknown primary brain metastasis, a diagnosis with a median expected survival of five months, was treated with Rigvir post-surgery [101].”
The authors would like to apologize for any inconvenience caused to the readers by these changes.
Reference
- McCarthy, C.; Jayawardena, N.; Burga, L.N.; Bostina, M. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
McCarthy, C.; Jayawardena, N.; Burga, L.N.; Bostina, M. Correction: McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. Cancers 2020, 12, 553. https://doi.org/10.3390/cancers12030553
AMA Style
McCarthy C, Jayawardena N, Burga LN, Bostina M. Correction: McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685. Cancers. 2020; 12(3):553. https://doi.org/10.3390/cancers12030553
Chicago/Turabian StyleMcCarthy, Cormac, Nadishka Jayawardena, Laura N. Burga, and Mihnea Bostina. 2020. "Correction: McCarthy, C.; et al. Developing Picornaviruses for Cancer Therapy. Cancers 2019, 11, 685" Cancers 12, no. 3: 553. https://doi.org/10.3390/cancers12030553
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
